Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Taking a BiTE Out of Cancer: An Interview With Micromet CEO Christian Itin

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

After securing $80.5 million in financing in August and renegotiating a partnership with MedImmune, Micromet is on course to take its first BiTE antibody into pivotal trials in 2010.

You may also be interested in...



Micromet Reacquires Full North American Rights To Blinatumomab

Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.

Micromet Reacquires Full North American Rights To Blinatumomab

Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.

Micromet Gets $12M Upfront From Sanofi For Discovery-Stage Oncology Antibody

This is Sanofi-Aventis' third oncology partnership this year, as it continues to seek new cancer drugs to replace Taxotere and Eloxatin.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS070049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By